Effect of IL-17A blockade with secukinumab in autoimmune diseases

Annals of the Rheumatic Diseases

Volumn 72, Issue SUPPL. 2, 2013, Pages

  Patel, Dhavalkumar D ^a   Lee, David M ^a   Kolbinger, Frank ^a   Antoni, Christian ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMG 139; BRODALUMAB; CHEMOKINE; CNTO 1959; CYCLOSPORIN; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 26; IXEKIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RG 4934; RG 7624; SCH 900117; SCH 900222; SECUKINUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CROHN DISEASE; DENDRITIC CELL; DISEASE ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; GENETIC ANALYSIS; HUMAN; INNATE IMMUNITY; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NEUTROPHIL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; T LYMPHOCYTE; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-17;

EID: 84876292569     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202371     Document Type: Article

References (56)

1. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011;23:613-19.
2. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
3. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
4. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76. (Pubitemid 39370503)
5. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011;12:1159-66.
6. Song X, Zhu S, Shi P, et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 2011;12:1151-8.
7. Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 2011;35:611-21.
8. Rong Z, Cheng L, Ren Y, et al. Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6. Cell Signal 2007;19:1514-20. (Pubitemid 46830879)
9. Rong Z, Wang A, Li Z, et al. IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res 2009;19:208-15.
10. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006;281:35603-7. (Pubitemid 46041290)
11. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010;10:479-89.
12. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8.
13. Puel A, Picard C, Cypowyj S, et al. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr Opin Immunol 2010;22:467-74.
14. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311-21.
15. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500.
16. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011;35:596-610.
17. Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5:e14108.
18. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538-52.
19. Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011;13:R95.
20. Suurmond J, Dorjée AL, Boon MR, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011;13:R150.
21. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012;2012:819467.
22. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11. (Pubitemid 351543220)
23. Xing Q, Wang B, Su H, et al. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012;32:949-58.
24. Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009;66:390-402.
25. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-61. (Pubitemid 47240944)
26. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev 2008;226:248-62.
27. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
28. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7. (Pubitemid 350138974)
29. Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 2009;106:13463-8.
30. Ivanov S, Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009;30:95-103.
31. Garber K. Psoriasis: from bed to bench and back. Nat Biotechnol 2011;29:563-6.
32. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010;9:703-18.
33. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
34. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87.
35. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60.
36. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
37. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
38. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
39. Papp KA, Sigurgeirrson B, Abe M, et al. Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis. Presented at: 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October, 2011, Lisbon, Portugal. Abstract 0626.
40. Rich PA, Guettner A, Sigurgeirsson B, et al. Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: a phase II regimen-finding trial (abstract). J Am Acad Dermatol 2012;66(Suppl 1):AB191.
41. Papp KA, Matheson RT, Tu JH, et al. Secukinumab, a novel fully human antibody to interleukin-17A, in the treatment of moderate-to-severe plaque psoriasis: efficacy and safety interim results from a phase II intravenous induction dose-ranging study. Presented at: 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October 2011, Lisbon, Portugal. Abstract 0630.
42. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
43. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009;219:209-18.
44. McInnes I, Sieper J, Braun J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial (abstract). Arthritis Rheum 2011;63(Suppl 10):779.
45. Genovese MC, Durez P, Richards HB, et al. One year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis (abstract). Arthritis Rheum 2011;63(Suppl 10):401.
46. Genovese M, Kellner H, Durez P, et al. Secukinumab treatment improves ACR50, HAQ-DI and EULAR remission rates in patients with rheumatoid arthritis (abstract). Ann Rheum Dis 2012;71(Suppl 3):191.
47. Durez P, Genovese M, Kellner H, et al. Lack of effect of secukinumab treatment on the lipid profile in patients with rheumatoid arthritis: results from a randomized, double-blind, placebo-controlled, phase II study (abstract). Ann Rheum Dis 2012;71 (Suppl 3):194.
48. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
49. Genovese MC, Greenwald MW, Cho CS, et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors (abstract). Arthritis Rheum 2011;63(Suppl 10):2591.
50. Genovese M, Greenwald M, Cho CS, et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors (abstract). Ann Rheum Dis 2012;71(Suppl 3):59.
51. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of ankylosing spondylitis (abstract). Ann Rheum Dis 2011;70(Suppl 3):127.
52. Baraliakos X, Braun J, Laurent DD, et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging (abstract). Arthritis Rheum 2011;63(Suppl 10):2486D.
53. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310-6.
54. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
55. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004;110:55-62. (Pubitemid 38177420)
56. U.S. National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov (accessed 30 Sep 2012).